Form 4: Korro Bio Inc. General Counsel Acquires 40,000 Stock Options
SEC Form 4 Filing
Jeffrey Cerio, General Counsel of Korro Bio, Inc., acquired 40,000 stock options on September 3, 2024, at an exercise price of $44.37.
Summary
- On September 3, 2024, Jeffrey Cerio, the General Counsel of Korro Bio, Inc., filed a Form 4.
- The filing reports the acquisition of 40,000 stock options.
- The exercise price of the options is $44.37.
- The options vest as to 25% on August 30, 2025, and the remainder vest in 36 equal monthly installments thereafter, contingent upon continued service.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a company officer.
Future Outlook
The vesting schedule indicates a long-term incentive plan for the General Counsel, aligning his interests with the company's performance over the next several years.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The stock option grant aligns the General Counsel's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of the transaction and filing of Form 4. |
| 08/30/2025 | First vesting date for 25% of the stock options. |
| 09/02/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.